Papers
1
Total Citations
142
H-Index
1
About
Bang‐Ce Ye is a pioneering researcher at the intersection of synthetic biology, biomaterials, and gastrointestinal disease. His most celebrated contribution is the development of a biomarker-responsive engineered probiotic that can diagnose, record, and even ameliorate inflammatory bowel disease (IBD) in living mice—a landmark study published in 2022 that has already garnered over 140 citations. This work exemplifies his core research focus: designing living therapeutics that sense and respond to disease microenvironments. Beyond this flagship achievement, Ye’s broader portfolio explores how engineered microbes and smart biomaterials can be used for targeted drug delivery, real-time disease monitoring, and personalized treatment. His innovative approach bridges fundamental microbiology with translational medicine, offering a paradigm shift from passive therapies to active, self-regulating biological systems. With a growing citation impact and a reputation for high-risk, high-reward science, Ye is shaping the future of precision probiotics and intelligent disease management.
Research Focus
Key Achievements
Top Papers
- 1